Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ClpV1-3 represents a family of three related AAA+ ATPases that are essential components of the Type VI secretion system (T6SS) in bacteria, particularly well-characterized in *Pseudomonas aeruginosa*. These proteins belong to the Clp/Hsp100 family of chaperone ATPases and play a crucial role in disassembling contracted TssBC sheath complexes following T6SS firing, allowing the system to be recycled for subsequent rounds of secretion. ClpV proteins contain characteristic structural features including an N-terminal domain with a unique helix (α0) that distinguishes them from other Hsp100 ATPases, two nucleotide-binding domains (NBD I and II) essential for ATP binding and hydrolysis, and a middle linker region. The N-terminal domain forms a hydrophobic groove that serves as the binding site for TssC proteins (sheath components). In *P. aeruginosa*, the three ClpV isoforms show high sequence similarity, particularly between ClpV2 and ClpV3, but exhibit differences in their binding pocket sizes and functional properties. ClpV3 specifically affects multiple virulence-related phenotypes including pyocyanin production, proteolytic activity, biofilm formation, and motility through modulation of second messenger levels (c-di-GMP and cAMP). These proteins represent potential antibacterial therapeutic targets as they are critical for bacterial virulence, competition, and pathogenesis, while being absent from human cells.
Not applicable as therapeutic agent (would be a target for inhibition in antibacterial therapy)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ClpV family Type VI secretion system ATPase (ClpV).